This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Without access to all the relevant data, researchers are unable to fully understand the complexities of diseases and develop effective treatments. This is especially true for registries outside of the United States where data is not as strictly regulated.
The fields of artificial intelligence (AI) and machine learning (ML) are increasingly influencing clinical research and development (R&D). Contract research organizations (CROs) and pharmaceutical companies can leverage these cutting-edge technologies to streamline clinical trials and introduce automation in drug discovery.
What we expect European regulators to do in June 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. Goodsell, Scripps Research and RCSB Protein Data Bank. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. Goodsell, Scripps Research and RCSB Protein Data Bank. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources.
Another challenge faced by international clinical trials is the lack of reliable data about local health systems and regulations. From legal considerations to data privacy regulations, the challenges facing these teams can be daunting. Additionally, clinical trials are no longer confined to one country or region.
What we expect European regulators to do in December 2023 In this new recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.
What we expect the EPA to do in April 2024 The top line: In this returning feature, AgencyIQ looks at public data to determine what the EPA is planning to do in the month ahead, including deadlines, meetings, events, planned regulations, comment periods, and more. PFAS regulations for drinking water.
Selecting an electronic institutional review board (eIRB) system is a critical decision for institutions looking to streamline their research compliance processes. Navigating the eIRB landscape can be overwhelming for researchers, human research protection program (HRPP) team members, and institutions alike.
The pressure to innovate quickly and sustainably is driving R&D teams to seek partnerships with researchers, startups and suppliers that specialize in emerging technologies. Several discussions at Future Food-Tech highlighted that scaling alternatives proteins globally is hindered by inconsistent regulations across regions.
When the CDC contacted Harris to ask about the plague samples, Harris claimed that he was doing research for the CIA to stop an “imminent invasion from Iraq of super-germ-carrying rats.” Starting in October, researchers receiving funds from the U.S. National Science Advisory Board for Biosecurity urged the U.S.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content